Dual co-agonist CI-1206 antagonizes Aβ1-42-induced impairments in spatial learning and memory in mice

doi:10.13459/j.cnki.cjap.2016.06.018

Abstract

Abstract: Objective: To study the neuroprotective effects of a novel GIP/GLP-1 receptor dual agonist CI-1206 against Aβ1-42-induced impairments in spatial working memory and long term memory in mice. Methods: C57 mice, after receiving intracerebralventricular (i.c.v.) injection of Aβ1-42 and intraperitoneal injection of CI-1206, were divided into the following groups:saline+D-PBS, Aβ1-42+saline, CI-1206+D-PBS and Aβ1-42+CI-1206 group (n=12). Y maze spontaneous alternation of mice was tested to assess short term working memory, and Morris water maze task was used to assess long term reference memory. Results: ①The percentage of right alternation of mice in Aβ1-42+saline group was significantly decreased, while the percentage in Aβ1-42+CI-1206 group was significantly larger than that in Aβ1-42 alone group (P<0.05). ②In Morris water maze test, the escape latency of mice in Aβ1-42+saline group showed a significant increase, with a significant decline in swimming time in target quadrant. Treatment with CI-1206 significantly antagonized these detrimental effects induced by Aβ1-42. ③Aβ1-42 and CI-1206 did not affect the motor ability and vision of mice. Conclusion: I.C.V. administration of Aβ1-42 impaired the short term and long term spatial memory of mice, while CI-1206 could effectively antagonize the detrimental effects.

Key words: CI-1206, Amyloid &beta, protein, Y-maze, Morris water maze, spatial learning and memory, mouse

CLC Number:

YANG Ju, ZHANG Jun, YUAN Li, QU Xue-song, QI Jin-shun. Dual co-agonist CI-1206 antagonizes Aβ1-42-induced impairments in spatial learning and memory in mice[J]. CJAP, 2016, 32(6): 567-570.

References

[1] Talbot K, Wang HY. The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease[J]. Alzheimers Dement, 2014, 10(1 Suppl):S12-25.
[2] Heppner FL, Ransohoff RM, Becher B. Immune attack:the role of inflammation in Alzheimer disease[J]. Nat Rev Neu-rosci, 2015, 16(6):358-372.
[3] Fraller DB. State of the science:use of biomarkers and imag-ing in diagnosis and management of Alzheimer disease[J]. J Neurosci Nurs, 2013, 45(2):63-70.
[4] Janson J, Laedtke T, Parisi JE, et al. Increased risk of type 2 diabetes in Alzheimer disease[J]. Diabetes, 2004, 53(2):474-481.
[5] Haan MN. Therapy insight:type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease[J]. Nat Clin Pract Neurol, 2006, 2(3):159-166.
[6] Gault VA, Porter WD, Flatt PR, et al. Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plas-ticity in mice fed a high-fat diet.[J]. Int J Obes(Lond), 2010, 34(8):1341-1344.
[7] Mc Clean PL, Gault VA, Harriott P, et al. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain:a link between diabetes and Alzheimer's disease[J]. Eur J Pharmacol, 2010, 630(1-3):158-162.
[8] Calsolaro V, Edison P. Novel GLP-1(Glucagon-Like Pep-tide-1) analogues and insulin in the treatment for Alzheimer's disease and other neurodegenerative diseases[J]. CNS Drugs, 2015, 29(12):1023-1039.
[9] Duffy AM, Hølscher C. The incretin analogue D-Ala2GIP re-duces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease[J]. Neuro-science, 2013, 228:294-300.
[10] Yu YW, Hsieh TH, Chen KY, et al. Glucose-dependent in-sulinotropic polypeptide ameliorates mild traumatic brain in-jury-induced cognitive and sensorimotor deficits and neuroin-flammation in rats[J]. J Neurotrauma, 2016.
[11] Finan B, Ma T, Ottaway N, et al. Unimolecular dual in-cretins maximize metabolic benefits in rodents, monkeys, and humans.[J]. Sci Transl Med, 2013, 5(209):209ra151.
[12] 李清山, 杨威, 潘艳芳, 等. 脑源性神经营养因子拮抗β淀粉样蛋白所致大鼠在体海马长时程增强的伤害[J]. 中国应用生理学杂志, 2012, 28(5):425-429.
[13] 郝明, 仝嘉庆, 张军, 等. 雷帕霉素对淀粉样β蛋白所致大鼠工作记忆和突触可塑性损伤的作用观察[J]. 中国应用生理学杂志, 2016, 32(1):18-21.
[14] Obregon D, Hou H, Deng J, et al. Soluble amyloid precur-sor protein-alpha modulates beta-secretase activity and amy-loid-beta generation[J]. Nat Commun, 2012, 3:777.
[15] Wang XH, Li L, Holscher C, et al. Val8-glucagon-like peptide-1 protects against Abeta1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats[J]. Neuroscience, 2010, 170(4):1239-1248.
[16] Tong JQ, Zhang J, Hao M, et al. Leptin attenuates the detrimental effects of beta-amyloid on spatial memory and hip-pocampal later-phase long term potentiation in rats[J]. Horm Behav, 2015, 73:125-130.
[17] Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents[J]. Nat Med, 2015, 21(1):27-36.
[18] Kastin A, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses[J]. Int J Obes Relat Metab Disord, 2003, 27(3):313-318.
[19] McClean PL, Hølscher C. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease[J]. Neuropharma-cology, 2014, 86:241-258.